About Commit Biologics

Commit Biologics has developed a Bispecific Complement Engaging (BiCE™) technology that activates the complement system to selectively target and kill tumor cells and cells involved in autoimmune diseases. This platform addresses the underutilization of the complement system in therapeutic applications, offering a new approach to treatment with the potential for reduced toxicity and enhanced efficacy.

```xml <problem> Current monoclonal antibody therapies often fail to effectively engage the complement system, limiting their ability to induce cell killing in cancer and autoimmune diseases. The complement system, a crucial part of the innate immune system, remains underexploited due to inherent difficulties in its activation by conventional antibodies. This underutilization hinders the development of effective treatments for various cancers and autoimmune disorders. </problem> <solution> Commit Biologics is developing Bispecific Complement Engaging (BiCE™) technology, a novel platform designed to potently activate the complement system for highly selective killing of tumor cells or cells implicated in autoimmune diseases. BiCE™ uses single-domain antibodies that bind to the complement protein C1q, directing the complement system in a targeted manner against cells of interest. This approach overcomes the limitations of conventional monoclonal antibodies, harnessing the power of the complement system to enhance therapeutic efficacy. By using established antibodies as a basis for developing therapeutics, Commit aims to reduce development times and mitigate risks associated with novel drug development. The BiCE™ technology addresses limitations of other approaches like antibody-drug conjugates and T-cell engagers, potentially enabling the development of effective therapeutic options with a broader therapeutic index. </solution> <features> - BiCE™ technology utilizes bispecific antibodies to bind both C1q and a target antigen on tumor or autoimmune cells. - Single-domain antibodies enable precise targeting and activation of the complement cascade. - Induces highly selective cell killing through complement-dependent cytotoxicity (CDC). - Designed to overcome limitations of conventional monoclonal antibodies in complement activation. - Potential for reduced toxicity compared to other immunotherapeutic approaches. - Applicable to a variety of cancers and autoimmune diseases. </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for cancer and autoimmune diseases, as well as patients who may benefit from more effective and less toxic treatment options. </target_audience> ```

What does Commit Biologics do?

When was Commit Biologics founded?

Commit Biologics was founded in 2021.

How much funding has Commit Biologics raised?

Commit Biologics has raised 17720000.

Founded

2021

Funding

17720000

Employees

19 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Commit Biologics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

commitbio.com 1K+

Crunchbase

Founded 2021

Funding

Estimated Funding

$10M+

Team (15+)

No team information available.

Company Description

Problem

Current monoclonal antibody therapies often fail to effectively engage the complement system, limiting their ability to induce cell killing in cancer and autoimmune diseases. The complement system, a crucial part of the innate immune system, remains underexploited due to inherent difficulties in its activation by conventional antibodies. This underutilization hinders the development of effective treatments for various cancers and autoimmune disorders.

Solution

Commit Biologics is developing Bispecific Complement Engaging (BiCE™) technology, a novel platform designed to potently activate the complement system for highly selective killing of tumor cells or cells implicated in autoimmune diseases. BiCE™ uses single-domain antibodies that bind to the complement protein C1q, directing the complement system in a targeted manner against cells of interest. This approach overcomes the limitations of conventional monoclonal antibodies, harnessing the power of the complement system to enhance therapeutic efficacy. By using established antibodies as a basis for developing therapeutics, Commit aims to reduce development times and mitigate risks associated with novel drug development. The BiCE™ technology addresses limitations of other approaches like antibody-drug conjugates and T-cell engagers, potentially enabling the development of effective therapeutic options with a broader therapeutic index.

Features

BiCE™ technology utilizes bispecific antibodies to bind both C1q and a target antigen on tumor or autoimmune cells.

Single-domain antibodies enable precise targeting and activation of the complement cascade.

Induces highly selective cell killing through complement-dependent cytotoxicity (CDC).

Designed to overcome limitations of conventional monoclonal antibodies in complement activation.

Potential for reduced toxicity compared to other immunotherapeutic approaches.

Applicable to a variety of cancers and autoimmune diseases.

Target Audience

The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapies for cancer and autoimmune diseases, as well as patients who may benefit from more effective and less toxic treatment options.